Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
0.263
+0.004 (1.55%)
At close: Nov 4, 2024, 4:00 PM
0.264
+0.001 (0.27%)
After-hours: Nov 4, 2024, 7:55 PM EST

Company Description

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases.

It’s XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.

The company’s product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps.

It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand.

The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018.

Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Lyra Therapeutics, Inc.
Lyra Therapeutics logo
Country United States
Founded 2005
IPO Date May 1, 2020
Industry Biotechnology
Sector Healthcare
Employees 88
CEO Maria Palasis

Contact Details

Address:
480 Arsenal Way
Watertown, Massachusetts 02472
United States
Phone 617 393 4600
Website lyratherapeutics.com

Stock Details

Ticker Symbol LYRA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001327273
CUSIP Number 55234L105
ISIN Number US55234L1052
SIC Code 3841

Key Executives

Name Position
Dr. Maria Palasis Ph.D. Chief Executive Officer, President and Director
Dr. Harlan W. Waksal M.D. Executive Chairman
Dr. Carmichael S. Roberts Jr., Ph.D. Co-Founder
Jason Cavalier Chief Financial Officer, Treasurer and Secretary
Ray Knox Vice President of Operations
Ronan P. O'Brien J.D. Chief Legal Officer
Vineeta Belanger Ph.D. Senior Vice President of Clinical Affairs
Dr. Robert Richard Ph.D. Senior Vice President of Technical Operations
Dr. Robert Kern M.D. Chief Clinical Advisor
Gloria Cosgrove Senior Vice President of Quality

Latest SEC Filings

Date Type Title
Aug 15, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Aug 14, 2024 10-Q Quarterly Report
Aug 14, 2024 8-K Current Report
Jul 23, 2024 8-K Current Report
Jun 18, 2024 8-K Current Report
Jun 7, 2024 8-K/A [Amend] Current report
May 21, 2024 8-K Current Report
Apr 30, 2024 10-Q Quarterly Report
Apr 30, 2024 8-K Current Report
Apr 29, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material